Eurofins Scientific SE

Equities

ERF

FR0014000MR3

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:55:00 19/01/2026 GMT			Pre-market 06:15:02
71.92 ^EUR	-0.28%		71.78	-0.19%

01-14	CIC Market Solutions Downgrades Eurofins Scientific to Neutral	MT
01-14	Nexus Infrastructure PLC Announces Appointment of Dr. Christian Wurst as Non-Executive Director, Effective January 14, 2026	CI

Eurofins: Weekly Report on Share Repurchases From 01st December to 05th December 2025

Published on 12/08/2025 at 04:45 pm GMT

Business Wire

Eurofins Scientific SE

-0.28%

Regulatory News:

Eurofins (Paris:ERF):

Name of the Issuer	Identify code of the Issuer	Transaction day	Identify code of the financial instrument	Total daily volume (in number of shares)	Daily weighted average purchase price of the shares	Market (MIC Code)
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	12/01/2025	FR0014000MR3	20 000	58.9527	XPAR
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	12/02/2025	FR0014000MR3	20 000	59.3808	XPAR
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	12/03/2025	FR0014000MR3	20 000	58.8687	XPAR
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	12/04/2025	FR0014000MR3	20 000	58.8292	XPAR
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	12/05/2025	FR0014000MR3	20 000	58.9334	XPAR
			TOTAL	100 000	58.9930

Transaction details

In accordance with Article 5(1)(b) of Regulation (EU) N° 596/2014 (the Market Abuse Regulation) a full breakdown of the individual trades are disclosed on Eurofins Scientific SE website: https://www.eurofins.com/investors/share-buy-back-programmes

View source version on businesswire.com: https://www.businesswire.com/news/home/20251208904512/en/

Latest news about Eurofins Scientific SE

01-14	CIC Market Solutions Downgrades Eurofins Scientific to Neutral	MT
01-14	Nexus Infrastructure PLC Announces Appointment of Dr. Christian Wurst as Non-Executive Director, Effective January 14, 2026	CI
01-05	Paris: Cautious Gains Cast in Wall Street's Shadow
01-05	CAC40 Remains Steady Despite Surprise U.S. Intervention in Venezuela
01-05	CAC40 Lags Behind Despite Record Highs in Europe and on Wall Street
01-05	BNP Paribas Upgrades Eurofins Scientific to Outperform Rating, Boosts PT	MT
01-05	Eurofins Soars, Boosted by Upbeat Exane Rating
01-05	Paris: Calm Start to the Year on the Stock Market Despite Maduro's Downfall in Venezuela
01-05	CAC40: Slight Uptick as Investors Brush Off Geopolitical Tensions
12-10	The Eurofins Consumer Product Testing Network Completes Significant Laboratory Expansion in Vietnam	CI
12-02	Eurofins Medical Device Services North America Launches First GMP Pfas Screening and Testing Solutions for Medical Devices	CI
11-05	CAC40 Attempts to Avoid a Seventh Consecutive Decline, Buoyed by Nasdaq Rebound
11-05	Paris Slows Further as Market Correction Looms
11-05	CAC 40 Continues Its Decline as Investors Remain Defensive
27/10/25	CAC 40 Edges Up Amidst Corporate Results and Monetary Policy Anticipation
23/10/25	AlphaValue/Baader Europe Cuts Eurofins Scientific Rating, Price Target	MT
23/10/25	Berenberg Maintains Eurofins Scientific at Hold Amid Continued BioPharma Segment Headwinds	MT
22/10/25	EUROFINS SCIENTIFIC : AlphaValue downgrades stock and lowers target price
22/10/25	AlphaValue/Baader Europe Downgrades Eurofins Scientific to Add, Cuts PT	MT
22/10/25	EUROFINS SCIENTIFIC : Resetting valuation and target price following transfer of coverage
21/10/25	Eurofins Scientific SE Reports Revenue Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
21/10/25	EUROFINS SCIENTIFIC : Q3 sales broadly in line, 2025 and 2027 targets reiterated
21/10/25	CAC40 Eyes New Highs with Edenred Surge, Gold Drops 4.4%
21/10/25	Eurofins Scientific SE, Nine Months 2025 Sales/ Trading Statement Call, Oct 21, 2025
21/10/25	CAC 40 Holds Steady, Boosted by Edenred but Dragged by Eurofins and BNP Paribas

Chart Eurofins Scientific SE

Duration

Period

ERF: Dynamic Chart

Company Profile

Eurofins Scientific SE is one of the world's leading providers of bio-analytical services. The group's services are intended to validate the safety, authenticity, origin, identity, and purity of biological substances contained in the environment (water, air, soil, etc.) and in food, pharmaceutical, cosmetic, and hygiene products. At the end of 2024, Eurofins Scientific SE owned a portfolio of over 200,000 analytical methods and had 950 laboratories located throughout the world. Net sales are distributed geographically as follows: Europe (51%), North America (38.3%) and other (10.7%).

Employees

65,000

Sector

Biotechnology & Medical Research

Calendar

01-28 - Q4 2025 Earnings Release

More about the company